+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein

Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein

European Journal of Pharmacology 504(1-2): 27-32

Recent studies demonstrate that multiple dopamine receptor subtypes contribute to the regulation of vesicular monoamine transporter-2 (VMAT-2) activity. The present studies extend these findings by demonstrating that administration of the nonselective dopamine D2 receptor family agonist, quinpirole, rapidly increased vesicular dopamine uptake in purified rat striatal vesicles. This effect occurred in both postnatal day 40 and 90 rats, and was associated with redistribution of the vesicular monoamine transporter-2 (VMAT-2) within nerve terminals. Neither a full nor a partial dopamine D1 receptor family agonist (SKF81297 nor SKF38393, respectively) affected vesicular dopamine uptake per se, nor the effect of quinpirole. Neither the dopamine D3 nor the D4 receptor antagonists, NGB2904 and clozapine, respectively, altered the quinpirole-mediated increase in uptake. However, the nonselective dopamine D2 receptor family antagonist, eticlopride, prevented the quinpirole-induced increase. Taken together, these data demonstrate that dopamine D2 receptor subtype activation increases vesicular dopamine uptake. Implications of this phenomenon with regard to the treatment of Parkinson's disease will be discussed.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 011975594

Download citation: RISBibTeXText

PMID: 15507217

DOI: 10.1016/j.ejphar.2004.09.049

Related references

Quinpirole increases vesicular dopamine uptake and redistributes vesicular monoamine transporter - 2 protein. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 373 12, 2003

Apomorphine Increases Vesicular Dopamine Uptake and Redistributes Vesicular Monoamine Transporter-2 Proteins. FASEB Journal 18(4-5): Abst 162 4, 2004

Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. Journal of Neuroscience 22(19): 8705-8710, 2002

Methylphenidate redistributes vesicular monoamine transporter-2 immunoreactivity Role of dopamine receptors. FASEB Journal 16(4): A585, 2002

Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61(7): 573-576, 2007

Drosophila vesicular monoamine transporter mutants can adapt to reduced or eliminated vesicular stores of dopamine and serotonin. Genetics 181(2): 525-541, 2009

Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. Plos one 7(11): E49483, 2012

Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Molecular Pharmacology 47(2): 368-373, 1995

Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. Journal of Neurochemistry 111(5): 1202-1212, 2009

Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Annals of Neurology 40(3): 428-439, 1996

Dopamine D2 receptor agonists increase vesicular monoamine transporter-2 function. FASEB Journal 17(4-5): Abstract No 645 5, 2003

Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2. Journal of Pharmacology and Experimental Therapeutics 336(3): 724-733, 2011

Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging. Journal Of Neural Transmission General Section. 97(2): 93-106, 1994

Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. Journal of Pharmacology and Experimental Therapeutics 310(3): 1142-1151, 2004

HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. Journal of Neuroimmune Pharmacology 7(3): 629-639, 2012